期刊
JOURNAL OF CLINICAL MEDICINE
卷 9, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/jcm9061870
关键词
non-small cell lung cancer; driver mutations; testing rates; receptor tyrosine kinases; team medicine
资金
- National Cancer Institute of Health [P30CA033572, U54CA209978, R01CA247471, R01CA218545]
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced with the identification of various key oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalizing therapy based on the molecular genomics of the tumor. This review presents approved treatments against actionable mutations in NSCLC as well as promising targets and therapies. We also discuss the current status of molecular testing practices in community oncology sites that would help to direct oncologists in lung cancer decision-making. We propose a collaborative framework between community practice and academic sites that can help improve the utilization of personalized strategies in the community, through incorporation of increased testing rates, virtual molecular tumor boards, vendor-based oncology clinical pathways, and an academic-type singular electronic health record system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据